Creative Biolabs is a professional drug development expert with extensive experience in virus screening, in vitro diagnosis, as well as pre-clinical research. We have won a good reputation among our worldwide customers for successfully accomplishing numerous challenging projects for coronavirus. We guarantee the finest results for our customers all over the world.
Recently, the rapid spread of 2019 novel coronavirus (SARS-CoV-2) has become a global public health issue. As a result, many attempts have been made in disease therapy and population control, but SARS-CoV-2 surveillance still needs to be improved. Real-time reverse transcription polymerase chain reaction (rRT-PCR) has been regarded as the gold standard for in vitro diagnostic of SARS-CoV-2 in human samples. However, this system also presents many limitations, such as high manpower and equipment resources, to detect the SARS-CoV-2 genome. In this condition, the establishment of effective viral screening systems should be beneficial to the rapid diagnostic capacity of SARS-CoV-2 in potential patients. Recently, reverse transcription loop-mediated isothermal amplification (RT-LAMP) has been proven its important role in the clinical diagnosis of SARS-CoV-2. In general, the results detected by RT-LAMP can be analyzed by the color change of PCR reaction tubes, which suggests this method can a simple, practical tool for monitoring SARS-CoV-2 infections in testing samples.
Fig.1 The sensitivity of the RT-LAMP compared with RT-PCR assay. (Du, 2019)
RT-LAMP is a promising tool that represents a fast, accurate detection process for the SARS-CoV-2 genome in different populations. Meanwhile, recent studies have also indicated that this method is suitable for large-scale screening of virus in low-resource scenarios. Therefore, Creative Biolabs has established a series of RT-LAMP-based assays for analyzing the novel SARS-CoV-2 in a cost-effective manner. Our RT-LAMP assays enable detecting potential SARS-CoV-2-affected samples as fast as 1-2 hours without highly trained staff and expensive equipment. Furthermore, we have also developed a one-step RT-LAMP platform to supervise SARS-CoV-2 susceptible populations, which can provide meaningful data for timely decisions targeting SARS-CoV-2 control strategies. In this platform, we are capable of quantifying and analyzing samples with the minimum concentration (10−5 PFU). In addition, the specificity of RT-LAMP assays has been already evaluated in both SARS-CoV-2 positive samples and negative control samples.
Creative Biolabs is a leader in the field of drug discovery and development and has focused on the treatment of coronavirus for years. Equipped with a team of experts and state-of-art technologies, we can offer high-quality SARS-CoV-2 drug discovery and customized RT-LAMP-based IVD kits development services for our clients to meet any requirement of your projects. If you are interested in our services, please contact us for more details.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.